Method for the synthesis of highly pure vaccines using the lipid core peptide system.
Traditional vaccines consisting of whole attenuated microorganisms, killed microorganisms, or microbial components, administered with an adjuvant (e.g. alum), have been proved to be extremely successful. However, to develop new vaccines, or to improve upon current vaccines, new vaccine development techniques are required. Peptide vaccines offer the capacity to administer only the minimal microbial components necessary to elicit appropriate immune responses, minimizing the risk of vaccination associated adverse effects, and focusing the immune response toward important antigens. Peptide vaccines, however, are generally poorly immunogenic, necessitating administration with powerful, and potentially toxic adjuvants. The attachment of lipids to peptide antigens has been demonstrated as a potentially safe method for adjuvanting peptide epitopes. The lipid core peptide (LCP) system, which incorporates a lipidic adjuvant, carrier, and peptide epitopes into a single molecular entity, has been demonstrated to boost immunogenicity of attached peptide epitopes without the need for additional adjuvants. The synthesis of LCP systems normally yields a product that cannot be purified to homogeneity. The current study describes the development of methods for the synthesis of highly pure LCP analogs using native chemical ligation. Because of the highly lipophilic nature of the LCP lipid adjuvant, difficulties (e.g. poor solubility) were experienced with the ligation reactions. The addition of organic solvents to the ligation buffer solubilized lipidic species, but did not result in successful ligation reactions. In comparison, the addition of approximately 1% (w/v) sodium dodecyl sulfate (SDS) proved successful, enabling the synthesis of two highly pure, tri-epitopic Streptococcus pyogenes LCP analogs. Subcutaneous immunization of B10.BR (H-2(k)) mice with one of these vaccines, without the addition of any adjuvant, elicited high levels of systemic IgG antibodies against each of the incorporated peptides.
Moyle
Peter M
PM
School of Molecular and Microbial Biosciences, The University of Queensland, St Lucia, Queensland, Australia.
Olive
Colleen
C
Good
Michael F
MF
Toth
Istvan
I
D000595:Amino Acid Sequence; D000818:Animals; D002851:Chromatography, High Pressure Liquid; D004339:Drug Compounding / Q000379:methods*; D000939:Epitopes / Q000737:chemistry / Q000276:immunology; D005260:Female; D007074:Immunoglobulin G / Q000097:blood; D008055:Lipids / Q000138:chemical synthesis / Q000737:chemistry* / Q000276:immunology; D051379:Mice; D015394:Molecular Structure; D010455:Peptides / Q000138:chemical synthesis* / Q000737:chemistry / Q000276:immunology; D021241:Spectrometry, Mass, Electrospray Ionization; D022541:Streptococcal Vaccines / Q000138:chemical synthesis / Q000276:immunology; D013297:Streptococcus pyogenes / Q000276:immunology; D014614:Vaccines, Synthetic / Q000737:chemistry* / Q000276:immunology
D000939:Epitopes; D007074:Immunoglobulin G; D008055:Lipids; D010455:Peptides; D022541:Streptococcal Vaccines; D014614:Vaccines, Synthetic